Novo Nordisk A/S$44.73ABT · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B | $31.90B | $30.58B |
| Cost of Revenue | $19.32B | $18.71B | $17.98B | $19.14B | $18.54B | $15.00B | $13.23B | $12.71B |
| Research & Development | $2.94B | $2.84B | $2.74B | $2.89B | $2.74B | $2.42B | $2.44B | $2.30B |
| Selling, General & Administrative | $12.33B | $11.70B | $10.95B | $11.25B | $11.32B | $9.70B | $9.77B | $9.74B |
| Operating Expenses | $36.27B | $35.13B | $33.63B | $35.29B | $34.65B | $29.25B | $27.37B | $26.93B |
| Operating Income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B | $5.36B | $4.53B | $3.65B |
| Interest Expense | — | — | $637.00M | $558.00M | $533.00M | $546.00M | $670.00M | $826.00M |
| Other Income / (Expense) | $548.00M | $376.00M | $479.00M | $321.00M | $277.00M | $103.00M | $191.00M | $139.00M |
| Income Before Taxes | $8.47B | $7.01B | $6.66B | $8.31B | $8.21B | $4.97B | $4.08B | $2.87B |
| Provision for Income Taxes | $1.94B | -$6.39B | $941.00M | $1.37B | $1.14B | $497.00M | $390.00M | $539.00M |
| Net Income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B | $2.37B |
| Basic EPS | $3.73 | $7.67 | $3.28 | $3.94 | $3.97 | $2.52 | $2.07 | $1.34 |
| Diluted EPS | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 | $2.06 | $1.33 |
| Basic Shares Outstanding | 1.74B | 1.74B | 1.74B | 1.75B | 1.77B | 1.77B | 1.77B | 1.76B |
| Diluted Shares Outstanding | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $5.52 | $5.48 | $5.55 | 11 | ↑8 ↓0 |
| Dec 2027 | $6.08 | $6.02 | $6.20 | 11 | ↑6 ↓1 |
| Dec 2028 | $6.74 | $6.71 | $6.81 | 4 | ↑2 ↓0 |
| Dec 2029 | $7.24 | $7.03 | $7.45 | 2 | ↑0 ↓0 |
